Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 98Lymphoid 28Thoracic 15Other hematologic neoplasm 14Gastrointestinal 9Sarcoma 8Plasma cell 5Genitourinary 4Dermatologic 2CNS 2Other 1Gynecologic 1

Conditions

Obesity 410Neoplasms 151Mucositis 128Sexual Dysfunction, Physiological 105Breast Neoplasms 105Polycystic Ovary Syndrome 98Overweight 98Dyspnea 62Constipation 57Motor Activity 54Head and Neck Neoplasms 47Prostatic Neoplasms 42Weight Loss 39Diabetes Mellitus 36Pain 34Colorectal Neoplasms 33Opioid-Induced Constipation 29Endometrial Neoplasms 29Stomatitis 28Lung Neoplasms 28Depression 26Diabetes Mellitus, Type 2 24Cardiovascular Diseases 23Obesity, Morbid 22Multiple Endocrine Neoplasia Type 1 22Insulin Resistance 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Anxiety Disorders 21Hypertension 19Sexual Dysfunctions, Psychological 18

Interventions

Hematologic Tests 1Echocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cardiotoxicity × Other × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡